ClinicalTrials.gg
CompletedNCT07937436772/EQL/2022Updated Nov 16, 2026

Bioequivalence Study of Sitagliptin/Metformin 50 mg/1000 mg Extended Release Tablet

An interventional study of Sitagliptin/metformin 50 mg/1000 mg extended release tablet and Janumet® XR 50 mg/1000 mg Extended Release Tablet produced by MSD International GmbH (Puerto Rico Branch) LLC, Puerto Rico, registered by PT Organon Pharma Indonesia Tbk., Indonesia) in Healthy Volunteers, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Dexa Medica Group · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Aug 2023, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The aim of the present study was to compare the bioavailability of sitagliptin/metformin 50 mg/1000 mg extended release tablet (produced by PT Dexa Medica) as the test drug with Janumet® XR 50 mg/1000 mg Extended-Release Tablet (produced by MSD International GmbH (Puerto Rico Branch) LLC, Puerto Rico, registered by PT Organon Pharma Indonesia Tbk., Indonesia) as the comparator drug, under fasting conditions with a seven-day wash-out period, involving 30 healthy adult male and female subjects.

Read the detailed description

This was an open-label, randomized, single-dose, two-period, two-sequence, crossover study under fasting conditions which included 30 healthy adult male and female subjects. The participating subjects were required to have an 8 hours overnight fast and in the next morning (first day of period) were given orally the test drug (sitagliptin/metformin 50 mg/1000 mg extended release tablet produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals) or the comparator drug (Janumet® XR 50 mg/1000 mg Extended Release Tablet produced by MSD International GmbH (Puerto Rico Branch) LLC, Puerto Rico, registered by PT Organon Pharma Indonesia Tbk., Indonesia) with total 240 mL of 20% glucose solution in water.

Blood samples were drawn before taking the drug (control), and at 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 24.00, 48.00, and 72.00 hours after drug administration. These blood samples were used to investigate the pharmacokinetic parameters of Sitagliptin and Metformin following single dose administration. The plasma concentrations of Sitagliptin and Metformin were determined by using validated ultra-performance liquid chromatography with tandem mass spectroscopy detection (UPLC-MS/MS method).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to participate, communicate well with the investigators and willing to provide written to participate in the study.
  2. Healthy male and female subjects with absence of significant disease or abnormal laboratory values on laboratory evaluation, medical history or physical examination during the screening and could be considered healthy based on the evaluation.
  3. Aged 18 - 55 years inclusive.
  4. Preferably non-smokers or smoke less than 10 cigarettes per day.
  5. within 18 to 25 kg/m2.
  6. Vital signs (after 10 minutes rest) must be within the following ranges: Systolic blood pressure : 100 - 129 mmHg, Diastolic blood pressure : 60 - 84 mmHg, Pulse rate : 60 - 90 bpm.
  7. Willing to practice abstention or non-hormonal during the study.

Exclusion criteria

Exclusion Criteria:

  1. History of allergy or or to sitagliptin, metformin, or allied drug.
  2. Pregnant or lactating female (urinary pregnancy test will be applied to female subjects at screening and before taking the study drug).
  3. Any major illness in the past 90 days or ongoing chronic medical illness.
  4. Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (, ALT, alkaline phosphatase, total , direct bilirubin ≥ 1.5 ), renal function test (serum creatinine concentration > 1.4 mg/dL and ureum ≥ 1.5 ULN), etc.
  5. Positive surface antigen (HBsAg), anti-, or anti-.
  6. Clinically significant hematology abnormalities.
  7. Clinically significant (ECG) abnormalities.
  8. Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery.
  9. Past history of anaphylaxis or angioedema.
  10. History of drug or alcohol abuse within 12 months prior to screening for this study.
  11. Participation in any clinical trial within the past 90 days calculated from the last visit until this study"s first dosing day.
  12. History of any bleeding or coagulative disorders.
  13. Presence of difficulty in accessibility of veins in left or right arm.
  14. A donation or significant blood loss within 90 days before this study"s first dosing day.
  15. Intake of any prescription (especially sitagliptin and metformin), non-prescription drug (including hormonal ), food supplements or herbal medicines within 21 days of this study"s first dosing day.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Test

    Test: Sitagliptin/metformin 50 mg/1000 mg extended release tablet at single dose was given to subejcts in this arm.

    Drug: Sitagliptin/metformin 50 mg/1000 mg extended release tablet

  • Active comparator
    Reference

    Janumet® XR 50 mg/1000 mg Extended Release Tablet produced by MSD International GmbH (Puerto Rico Branch) LLC, Puerto Rico, registered by PT Organon Pharma Indonesia Tbk., Indonesia) was given to subjecsts in this arm.

    Drug: Janumet® XR 50 mg/1000 mg Extended Release Tablet produced by MSD International GmbH (Puerto Rico Branch) LLC, Puerto Rico, registered by PT Organon Pharma Indonesia Tbk., Indonesia)

Interventions

  • DrugSitagliptin/metformin 50 mg/1000 mg extended release tablet

    Test: Sitagliptin/metformin 50 mg/1000 mg extended release tablet. One tablet of the Test drug was given orally (swallowed with 240 mL of 20% glucose solution in water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.

    Also known as: Test

  • DrugJanumet® XR 50 mg/1000 mg Extended Release Tablet produced by MSD International GmbH (Puerto Rico Branch) LLC, Puerto Rico, registered by PT Organon Pharma Indonesia Tbk., Indonesia)

    Reference: One tablet of the Reference drug was given orally (swallowed with 240 ml of 20% glucose solution in water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.

    Also known as: Reference

06

What researchers measure

Primary outcomes

  1. AUC0-t

    The area under plasma concentration curve from administration to last observed concentration at time t.

    Time frame: 72 hours

  2. Cmax

    Maximum plasma concentration

    Time frame: 72 hours

Secondary outcomes

  1. Tmax

    Time to maximum plasma concentration

    Time frame: 72 hours

  2. T1/2

    The terminal half-life

    Time frame: 72 hours

  3. AUC0-inf

    The area under plasma concentration-time curve extrapolated to infinite time

    Time frame: 72 hours

07

Study locations

1 site
  • PT Equilab International
    Jakarta, Jakarta Special Capital Region 12430, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Aug 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Aug 9, 2023
Primary completionActual
Aug 9, 2023
CompletionActual
Aug 19, 2023
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937436
Lead sponsor
Dexa Medica Group
Collaborators
PT Equilab International
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Aug 9, 2023
Primary completion
Aug 9, 2023
Completion
Aug 19, 2023
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion